ETR:EVT Evotec (EVT) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free EVT Stock Alerts €14.38 +0.61 (+4.43%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range€13.76▼€14.4550-Day Range€12.62▼€15.2852-Week Range€12.61▼€24.44Volume714,193 shsAverage Volume1.36 million shsMarket Capitalization$2.55 billionP/E RatioN/ADividend Yield2.63%Price Target€21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesStock AnalysisAnalyst ForecastsChartHeadlines Get Evotec alerts: Email Address Evotec MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside46.1% Upside€21.00 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.35 out of 5 stars 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of €21.00, Evotec has a forecasted upside of 46.1% from its current price of €14.38.Amount of Analyst CoverageEvotec has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for EVT. Previous Next 0.8 Dividend Strength Dividend YieldEvotec pays a meaningful dividend of 2.63%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthEvotec does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVT. Previous Next 1.0 News and Social Media Coverage News SentimentEvotec has a news sentiment score of -1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.Search Interest4 people have searched for EVT on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evotec insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.21% of the stock of Evotec is held by insiders.Percentage Held by Institutions47.32% of the stock of Evotec is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Evotec is -27.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evotec is -27.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioEvotec has a PEG Ratio of 0.98. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioEvotec has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Evotec Stock (ETR:EVT)Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.Read More EVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVT Stock News HeadlinesMarch 15, 2024 | finanznachrichten.deEvotec-Aktie: Das wird spannendMarch 6, 2024 | markets.businessinsider.comEQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinicMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 22, 2024 | finanznachrichten.deEvotec Aktie sucht Boden: Kommt jetzt die große Wende nach oben?Evotec Aktie sucht Boden: Kommt jetzt die große Wende nach oben?February 6, 2024 | finanznachrichten.deEvotec: Aktie fällt und fällt - das ist jetzt wichtigFebruary 3, 2024 | finanznachrichten.deEvotec-Aktie fällt unter wichtige Marke. Wie sollen Anleger jetzt reagieren?January 22, 2024 | finance.yahoo.comEvotec SE: Invitation to Conference CallJanuary 8, 2024 | markets.businessinsider.comEQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers SquibbMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.January 8, 2024 | finance.yahoo.comEvotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers SquibbJanuary 3, 2024 | markets.businessinsider.comEQS-Adhoc: Evotec announces CEO transitionJanuary 3, 2024 | finanznachrichten.deEvotec SE: Evotec Announces CEO TransitionJanuary 3, 2024 | markets.businessinsider.comEQS-News: Evotec announces CEO transitionJanuary 3, 2024 | finance.yahoo.comEvotec Announces CEO TransitionDecember 14, 2023 | finance.yahoo.comEvotec Enters Partnership with Charité to Expand Molecular Patient Database in Autoimmune DiseasesDecember 6, 2023 | msn.comEvotec partner Jingxin receives approval for EVT201 in ChinaDecember 6, 2023 | markets.businessinsider.comEQS-News: Evotec-partner Jingxin receives approval for EVT201 in ChinaNovember 8, 2023 | markets.businessinsider.comEvotec 9-month Adj. EBITDA, Revenues Rise; Confirms FY23, Mid-term OutlookNovember 8, 2023 | finance.yahoo.comEvotec SE Reports Results for the First Nine Months 2023 and Provides Corporate UpdateNovember 7, 2023 | fxstreet.comFlat start to Monday after global equities posted best week in a yearOctober 6, 2023 | finance.yahoo.comFurther weakness as Evotec (ETR:EVT) drops 6.5% this week, taking three-year losses to 23%October 5, 2023 | markets.businessinsider.comEQS-News: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'September 27, 2023 | markets.businessinsider.comEQS-News: Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economySeptember 26, 2023 | finance.yahoo.comEvotec and Novo Nordisk Launch LAB eN(2) to Accelerate Translation in Cardiometabolic DiseasesAugust 29, 2023 | markets.businessinsider.comEQS-News: Evotec SE reports results for the first half-year 2023 and provides corporate updatesJuly 28, 2023 | markets.businessinsider.comEQS-Adhoc: Evotec provides update on financial impact of cyber-attackJuly 28, 2023 | markets.businessinsider.comEQS-News: Evotec provides update on financial impact of cyber-attackSee More Headlines Receive EVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolETR:EVT CUSIPN/A CIKN/A Webwww.evotec.com Phone+49-40-560810FaxN/AEmployees5,086Year FoundedN/APrice Target and Rating Average Stock Price Target€21.00 High Stock Price Target€21.00 Low Stock Price Target€21.00 Potential Upside/Downside+46.1%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)(€0.53) Trailing P/E RatioN/A Forward P/E Ratio69.25 P/E Growth0.98Net Income$-94,980,000.00 Net Margins-11.57% Pretax MarginN/A Return on Equity-8.02% Return on Assets0.17% Debt Debt-to-Equity Ratio51.61 Current Ratio2.16 Quick Ratio2.97 Sales & Book Value Annual Sales$820.80 million Price / Sales3.10 Cash Flow€4.16 per share Price / Cash Flow3.45 Book Value€6.45 per share Price / Book2.23Miscellaneous Outstanding Shares177,190,000Free FloatN/AMarket Cap$2.55 billion OptionableNot Optionable Beta1.09 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Mario Polywka DPHIL (Age 61)Ph.D., Interim CEO, Member of the Management Board & Member of the Supervisory Board Dr. Werner Lanthaler M.B.A. (Age 56)MPA, Ph.D., Member of Management Board Comp: $1.32MDr. Cord Dohrmann Ph.D. (Age 60)Chief Scientific Officer & Member of Management Board Comp: $804kDr. Craig Johnstone Ph.D. (Age 54)COO & Member of Management Board Comp: $712kDr. Matthias Evers Ph.D. (Age 51)Chief Business Officer & Member of Management Board Comp: $636kMs. Laetitia Rouxel (Age 50)CFO & Member of Management Board Ms. Anja BoslerPrincipal Accounting Officer and Senior Vice President of Group AccountingMr. Volker BraunSenior VP and Global Head of Investor Relations & ESGDr. Christian DargelEVP Global Head of Legal & ComplianceGabriele HansenSenior VP & Head of Global Corporate Communications & MarketingMore ExecutivesKey CompetitorsMorphoSysETR:MORShop Apotheke EuropeETR:SAEGerresheimerETR:GXICompuGroup Medical SE & Co. KGaAETR:COPBiotest AktiengesellschaftETR:BIOView All Competitors EVT Stock Analysis - Frequently Asked Questions What is Evotec's stock price target for 2024? 0 Wall Street analysts have issued 1-year price targets for Evotec's shares. Their EVT share price targets range from €21.00 to €21.00. On average, they predict the company's stock price to reach €21.00 in the next year. This suggests a possible upside of 46.1% from the stock's current price. View analysts price targets for EVT or view top-rated stocks among Wall Street analysts. How have EVT shares performed in 2024? Evotec's stock was trading at €21.28 at the start of the year. Since then, EVT shares have decreased by 32.4% and is now trading at €14.38. View the best growth stocks for 2024 here. What other stocks do shareholders of Evotec own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC). This page (ETR:EVT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.